ArticleWorld journal of gastroenterology2011
18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer.
Article in World journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 45 citations in OpenAlex.
- Diagnostic Method Advancement to Improve the Prognosis of Pancreatic Ductal Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2026Review
- [American journal of nuclear medicine and molecular imaging · 2024Article
- The Value of Circulating Tumor Cells in the Prognosis and Treatment of Pancreatic Cancer.Frontiers in oncology · 2022Review
- Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review.Insights into imaging · 2020Review
- Conversion Therapy for Advanced Pancreatic Cancer: The Case Series and Literature Review.Frontiers in pharmacology · 2020Article
- Natural History of Pancreatic Ductal Adenocarcinoma Diagnosed During Observation of Other Organ Cancers.The American journal of case reports · 2019Article
- Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club.Przeglad gastroenterologiczny · 2019Article
- Challenges in diagnosis of pancreatic cancer.World journal of gastroenterology · 2018Review
- Review
- Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer.World journal of gastroenterology · 2015Article
- Diagnostic strategies for early pancreatic cancer.Journal of gastroenterology · 2015Review
- Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma.BioMed research international · 2015Article
- Strategies for early detection of resectable pancreatic cancer.World journal of gastroenterology · 2014Review
- Pancreatic cancer: translational research aspects and clinical implications.World journal of gastroenterology · 2012Article
- Article
- State-of-the-art PET/CT of the pancreas: current role and emerging indications.Radiographics : a review publication of the Radiological Society of North America, IncArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the role of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) in the diagnosis of small pancreatic cancer.
methodsThis study involved 31 patients with proven invasive ductal cancer of the pancreas. The patients were divided into 3 groups according to the maximum diameter of the tumor: TS1 (maximum tumor size ≤ 2.0 cm), TS2 (> 2.0 cm and ≤ 4.0 cm) or TS3-4 (> 4.0 cm). The relationships between the TS and various diagnostic tools, including FDG-PET with dual time point evaluation, were analyzed.
resultsThe tumors ranged from 1.3 to 11.0 cm in diameter. Thirty of the 31 patients (97%) had a positive FDG-PET study. There were 5 patients classified as TS1, 15 as TS2 and 11 as TS3-4. The sensitivity of FDG-PET, computed tomography (CT) and magnetic resonance imaging (MRI) were 100%, 40%, 0% in TS1, 93%, 93%, 89% in TS2 and 100%, 100%, 100% in TS3-4. The sensitivity of FDG-PET was significantly higher in comparison to CT and MRI in patients with TS1 (P < 0.032). The mean standardized uptake values (SUVs) did not show a significant difference in relation to the TS (TS1: 5.8 ± 4.5, TS2: 5.7 ± 2.2, TS3-4: 8.2 ± 3.9), respectively. All the TS1 tumors (from 13 to 20 mm) showed higher SUVs in FDG-PET with dual time point evaluation in the delayed phase compared with the early phase, which suggested the lesions were malignant.
conclusionThese results indicate that FDG-PET with dual time point evaluation is a useful modality for the detection of small pancreatic cancers with a diameter of less than 20 mm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.